← back to search

Benjamin Brady

Worcester Polytechnic Institute · US
Area of research
Oncology · Molecular Biology
Research interest
Research interests include Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management, and CAR-T cell therapy research.
h-index
14
citations
7,042
works
31
NIH funding
primary concept
Medicine
email

Recent publications

Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma
Journal of Clinical Oncology 2020cited by 223position: middledoi
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
JAMA Oncology 2018cited by 343position: middledoi
Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series
European Journal of Cancer 2018cited by 92position: middledoi
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Journal of Clinical Oncology 2017cited by 639position: middledoi
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
Journal of Translational Medicine 2015cited by 53position: middledoi
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
New England Journal of Medicine 2014cited by 5,336position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Kerry J. Savage · BC Cancer Agency2 papers (2015–2017)Célèste Lebbé · Assistance Publique – Hôpitaux de Paris2 papers (2015–2017)Jessica C. Hassel · Praxis für Hämatologie und Onkologie2 papers (2015–2017)J. Charles · Centre National de la Recherche Scientifique2 papers (2015–2017)Christine E. Horak · Laboratory of Molecular Genetics1 papers (2015–2015)Victoria Atkinson · Princess Alexandra Hospital1 papers (2015–2015)Joel Jiang · Johnson & Johnson (United States)1 papers (2017–2017)Mario Sznol · Yale Cancer Center1 papers (2017–2017)Michele Maio · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori1 papers (2015–2015) · 1 papers (2015–2015)Ian M. Waxman · Bristol-Myers Squibb (United States)1 papers (2015–2015)Paolo A. Ascierto · Parker Institute for Cancer Immunotherapy1 papers (2015–2015)Vanna Chiarion‐Sileni · Istituto Oncologico Veneto1 papers (2015–2015)Dirk Schadendorf · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori1 papers (2015–2015)Alexander N. Shoushtari · Humboldt-Universität zu Berlin1 papers (2017–2017)Peter Mohr · Elbe Kliniken Stade-Buxtehude1 papers (2017–2017)Jeffrey S. Weber · Heinrich Heine University Düsseldorf1 papers (2017–2017)Wilson H. Miller · Colorado State University1 papers (2017–2017)Jedd D. Wolchok · Cornell University1 papers (2017–2017)Mary Ruisi · Dragonfly Therapeutics (United States)1 papers (2017–2017)